Latest News
-
Wednesday - December 4, 2019
Digital transformation
New set-up for IT at Bayer
Specialized external partners to take over standardized IT services / Internal delivery to focus on IT activities that differentiate Bayer from its competitors » more
-
Friday - November 29, 2019
Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets
Further step in Bayer’s efforts to sharpen focus on core business » more
-
Thursday - November 28, 2019
Bayer selects Pharmaron as partner organization
Global collaboration for CMC development of small molecules » more
-
Monday - November 25, 2019
Not intended for U.S. and UK Media
Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolism
Adding treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis / Submission based on results from phase 3 EINSTEIN-Jr. study showing convincing efficacy and safety profile for rivaroxaban in children with VTE / An oral liquid formulation of rivaroxaban that does not require injections and regular monitoring was developed to facilitate pediatric administration / Patent extension in Europe of six months will be applied for once the procedure is completed » more
-
Tuesday - November 19, 2019
Not intended for U.S. and UK Media - Neglected Tropical Diseases
Bayer expands collaboration with the World Health Organization to fight pork tapeworm infections as cause for epilepsy
5-year agreement on drug donation and financial support to treat infection with pork tapeworm T. solium (taeniasis) / Tissue infections in the brain caused by larvae of pork tapeworm / (neurocystercosis) are the most frequent cause of epilepsy in low- and middle-income countries / Control of taeniasis and neurocystercosis as cause of epilepsy in the focus of the new Neglected Tropical Diseases (NTD) Roadmap 2021 - 2030 of the World Health Organization » more
-
Monday - November 18, 2019
Not intended for U.S. and UK Media
Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint
Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failure » more
-
Thursday - November 14, 2019
Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases
Bayer contributes up to USD 100 million / Dewpoint’s drug platform targets biomolecular condensates, dynamic cellular structures newly understood to be central to many disease mechanisms / Biomolecular condensates expand traditional drug target space for small molecules » more
-
Sunday - November 10, 2019
Climate FieldView™ Partnership with CLAAS Brings Bayer Data Science to More Farms:
Global agreement supports FieldView expansion in Europe and other regions » more
-
Thursday - November 7, 2019
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer refinances 1.75 billion euro hybrid bond
New issue of two tranches with a non-call period of 5.5 and 8 years combined with a tender offer for Bayer’s existing hybrid bond » more
-
Thursday - November 7, 2019
Bayer invests USD 50 Million in eGenesis Series B financing round
Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation » more
-
Monday - November 4, 2019
Bayer completes sale of Dr. Scholl’s™ brand to Yellow Wood Partners » more
-
Monday - November 4, 2019
Youth leaders take on the fight to feed a hungry planet
3-day Youth Ag Summit kicks off in Brasilia, Brazil on 4 November 2019 / One hundred young change-makers, representing 45 countries, gather to turn their ideas for food security into reality » more
-
Wednesday - October 30, 2019
Bayer AG Third Quarter 2019 Results and News Conference Call » more
-
Wednesday - October 30, 2019
Third quarter of 2019
Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health
Group sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros / EBITDA before special items advances by 7.5 percent to 2.291 billion euros / Crop Science reports higher sales and substantial earnings growth / Pharmaceuticals increases sales – earnings decline due to one-time income in prior year / Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings / Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year / Core earnings per share up by 6.4 percent to 1.16 euros / Group outlook confirmed and aligned to continuing operations » more
-
Tuesday - October 22, 2019
2019 World Para Athletics Championships in Dubai
Large Number of Bayer athletes competing in German team
2019 World Championships taking place in Dubai from November 7-15 / 10 out of 34 athletes from Bayer club compete for Germany / Bayer committed to supporting disabled sports » more
-
Monday - October 21, 2019
Bayer at the Annual Biocontrol Industry Meeting 2019:
“Biologicals by Bayer”, leading innovation for organic crop protection solutions » more
-
Wednesday - October 16, 2019
Bayer Animal Health and VLPbio sign global collaboration agreement
Bayer Animal Health to strengthen its technology portfolio for biological products » more
-
Monday - October 14, 2019
Not intended for U.S. and UK Media
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE » more
-
Monday - October 14, 2019
Neptra® receives positive CVMP opinion for launch in Europe
Bayer's Neptra® ear drops solution for dogs treats susceptible strains of common pathogens found in canine otitis externa. » more
-
Thursday - October 10, 2019
Bayer inks deals with eleven startups under G4A Digital Health Partnerships program
Eleven healthcare startup companies to be supported by Bayer’s “G4ADigital Health Partnerships program” to drive forward innovative digital health solutions for patients / Includes financial funding, commercial partnerships in areas of cardiovascular health, oncology, ophthalmology, pulmonology, radiology, digital therapeutics » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
Bayer TV